09/03/2015 // JusticeNewsFlash // (press release)
Dallas – Claims about adverse reactions in patients taking the blood-thinning medication Xarelto are being investigated by a national law firm. As reported on Yahoo! Finance, the drug distributed by Janssen Pharmaceuticals in the U.S. has allegedly been linked to multiple health complications including excessive internal bleeding and hemorrhagic strokes.
Xarelto was approved by the U.S. Food and Drug Administration in 2011 for the prevention of blood clots and the treatment of existing blood clots in patients. An article published in the JAMA Ophthalmology’s June 15 issue noted reports by doctors about several elderly patients who experienced bleeding of the eye after switching to the medication from a different blood thinning drug.
Russell Budd, who is president and managing shareholder of the national law firm of Baron & Budd, is quoted as stating of the reports “There have been far too many instances of patients taking this drug and suffering devastating side effects…Pharmaceutical companies owe it to patients to introduce the safest possible products to the marketplace, and must be held accountable when they are found to be negligent in this obligation.”